Considering Allergan’s Q2 2018 Revenue Trend

Allergan’s revenue

As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.

Considering Allergan’s Q2 2018 Revenue Trend

The chart above compares Allergan’s revenues since the first quarter of 2017.

Second-quarter revenues

In the second quarter, Allergan surpassed Wall Street analysts’ estimates for EPS and revenue and reported non-GAAP (generally accepted accounting principles) EPS of $4.42 on revenue of $4.1 billion compared to the estimates $4.12 and $3.9 billion.

Allergan’s business is separated into the US and international categories. Its US business is further classified into the Specialized Therapeutics and General Medicines segments. The company reports its business revenues and performance based on three business segments:

  • US Specialized Therapeutics
  • US General Medicines
  • International Business

The US Specialized Therapeutics segment and the International Business segment reported revenue rises during the second quarter, while its growth was partially offset by lower revenue from its US General Medicines segment.

The US Specialized Therapeutics segment reported a 6.5% rise in YoY sales to $1.83 billion during the second quarter, while the US General Medicines segment reported a 7.5% fall in YoY sales to $1.32 billion during the quarter. The International Business segment’s revenue rose 10.5% YoY to $949 million during the second quarter, including an 8.1% increase in operating revenue.

The VanEck Vectors Biotech ETF (BBH) holds 5.5% of its total investments in Allergan, 9.7% in Amgen (AMGN), 8.9% in Gilead Sciences (GILD), and 5.9% in Celgene (CELG).